Acrivon Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Acrivon Therapeutics, Common
ACRV Stock   5.79  0.24  4.32%   
Acrivon Therapeutics, financial statements provide useful quarterly and yearly information to potential Acrivon Therapeutics, Common investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Acrivon Therapeutics, financial statements helps investors assess Acrivon Therapeutics,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Acrivon Therapeutics,'s valuation are summarized below:
Market Capitalization
172.8 M
Earnings Share
(2.66)
There are over one hundred nineteen available fundamental signals for Acrivon Therapeutics, Common, which can be analyzed over time and compared to other ratios. All traders should should validate Acrivon Therapeutics,'s prevailing fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to drop to about 118.7 M in 2025. Enterprise Value is likely to drop to about 84.4 M in 2025
Check Acrivon Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acrivon Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 479.9 K, Selling General Administrative of 25.5 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.85. Acrivon financial statements analysis is a perfect complement when working with Acrivon Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Acrivon Therapeutics, Correlation against competitors.

Acrivon Therapeutics, Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets117.8 M159 M45.4 M
Slightly volatile
Short and Long Term Debt Total4.2 M5.3 M1.6 M
Slightly volatile
Other Current Liabilities8.9 M8.5 M2.2 M
Slightly volatile
Total Current Liabilities16.1 M15.3 M3.8 M
Slightly volatile
Property Plant And Equipment Net5.7 M9.1 M2.2 M
Slightly volatile
Accounts Payable6.1 M5.8 M1.3 M
Slightly volatile
Cash45.8 M41.4 M16.9 M
Slightly volatile
Non Current Assets Total18.9 M9.9 M6.4 M
Slightly volatile
Non Currrent Assets Other274.2 K288.6 K650.7 K
Pretty Stable
Other Assets0.860.9328.3 K
Slightly volatile
Cash And Short Term Investments98 M146.6 M38.6 M
Slightly volatile
Common Stock Shares Outstanding23.6 M25.4 M21.5 M
Slightly volatile
Liabilities And Stockholders Equity117.8 M159 M45.4 M
Slightly volatile
Non Current Liabilities Total3.2 M3.4 M15.7 M
Pretty Stable
Other Current Assets2.1 M2.6 M844.7 K
Slightly volatile
Other Stockholder Equity287 M273.3 M64.2 M
Slightly volatile
Total Liabilities14.6 M15.4 M19 M
Pretty Stable
Property Plant And Equipment Gross6.1 M10.2 M2.4 M
Slightly volatile
Short and Long Term Debt46.4 K52.2 K56.9 K
Slightly volatile
Total Current Assets98.9 M149.1 M39 M
Slightly volatile
Capital Stock27.8 K26.4 K7 K
Slightly volatile
Net Working Capital93.7 M133.8 M36.2 M
Slightly volatile
Short Term Debt839 K1 M342.4 K
Slightly volatile
Common Stock27.8 K26.4 K7 K
Slightly volatile
Property Plant Equipment2.9 M2.4 M996.4 K
Slightly volatile
Current Deferred Revenue74.2 K79.3 K67.7 K
Slightly volatile
Common Stock Total Equity17.6 K19.8 K21.6 K
Slightly volatile
Capital Surpluse181.3 M203.9 M222.3 M
Slightly volatile
Non Current Liabilities Other3.4 M3.8 M4.2 M
Slightly volatile

Acrivon Therapeutics, Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization479.9 K616.4 K185.7 K
Slightly volatile
Selling General Administrative25.5 M24.2 M6 M
Slightly volatile
Other Operating Expenses81.2 M77.3 M19.3 M
Slightly volatile
Research Development54.9 M52.3 M13.2 M
Slightly volatile
Cost Of Revenue680.9 K616.4 K244 K
Slightly volatile
Total Operating Expenses80.5 M76.7 M19.2 M
Slightly volatile
Reconciled Depreciation618.2 K588.8 K141.4 K
Slightly volatile
Interest Expense1.8 M1.7 M450 K
Slightly volatile
Non Operating Income Net Other1.2 M1.3 M1.5 M
Slightly volatile
Selling And Marketing Expenses107.2 K120.6 K131.5 K
Slightly volatile

Acrivon Therapeutics, Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings46.4 K52.2 K56.9 K
Slightly volatile
Stock Based Compensation14 M13.4 M2.6 M
Slightly volatile
Begin Period Cash Flow36.8 M34.4 M14 M
Slightly volatile
Depreciation647.2 K616.4 K146.5 K
Slightly volatile
Other Non Cash Items868 K957.6 K1.7 M
Slightly volatile
Capital Expenditures1 M1.5 M397.4 K
Slightly volatile
End Period Cash Flow46.3 M41.9 M17.3 M
Slightly volatile
Change To Netincome2.3 M2.5 M2.2 M
Pretty Stable
Sale Purchase Of Stock81.4 M91.5 M99.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation3.182.162.0511
Slightly volatile
Payables Turnover0.09080.09560.2137
Slightly volatile
Cash Per Share3.295.21.6063
Slightly volatile
Days Payables Outstanding2.2 K4 K3.3 K
Slightly volatile
Income Quality0.620.640.6003
Slightly volatile
Net Debt To EBITDA0.570.60.7361
Pretty Stable
Current Ratio13.328.777.2968
Slightly volatile
Graham Number17.3716.545.5541
Slightly volatile
Capex Per Share0.03380.05250.0164
Slightly volatile
Interest Debt Per Share0.140.190.0667
Slightly volatile
Debt To Assets0.03860.03360.0302
Slightly volatile
Days Of Payables Outstanding2.2 K4 K3.3 K
Slightly volatile
Ebt Per Ebit1.241.031.4719
Slightly volatile
Effective Tax Rate0.02580.0430.0361
Very volatile
Quick Ratio13.328.777.2968
Slightly volatile
Net Income Per E B T0.760.860.9344
Slightly volatile
Cash Ratio2.963.114.7434
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.820.930.9955
Slightly volatile
Debt Ratio0.03860.03360.0302
Slightly volatile

Acrivon Therapeutics, Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap118.7 M124.9 M298.1 M
Slightly volatile
Enterprise Value84.4 M88.8 M283.3 M
Slightly volatile

Acrivon Fundamental Market Drivers

Cash And Short Term Investments127.5 M

Acrivon Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Acrivon Therapeutics, Financial Statements

Acrivon Therapeutics, investors use historical fundamental indicators, such as Acrivon Therapeutics,'s revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Acrivon Therapeutics,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue79.3 K74.2 K
Cost Of Revenue616.4 K680.9 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Acrivon Stock Analysis

When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY